To determine whether other enzymes involved in the metabolism of sphingolipids could be potential targets in CLL, inhibitors targeting sphingosine kinases, SKI-II and sphingosine kinase 1, fingolimod, along with the ceramide synthase inhibitor (CERS) fumonisin B1 were evaluated (Supplementary Fig. 1). Here, TLCD3B is linked to B-cell chronic lymphocytic leukemia.